Novavax Inc. shares shares sank in the extended session Tuesday after the biotech drug maker posted more than double the loss that analysts expected, and reorganized with concerns it may not be in bus...
Tag: Medical Treatments/Procedures
Novavax Says ‘Substantial Doubt’ Around Its Continuing Operations
Covid-19 vaccine manufacturer Novavax said Tuesday that there is “substantial doubt” about its ability to continue operating through this year. In a quarterly earnings report issued after the market c...
Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done
An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...
Pfizer CEO: Covid Infections Will Rise. So Will Paxlovid and Vaccine Sales.
Pfizer executives say Wall Street analysts haven’t understood just how powerful a hit the company’s Covid-19 products will take this year. That’s the explanation the company’s chief financial officer,...
Exxon Mobil Stock Should Shine, Even in a Recession
These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or rec...
BioNTech upgraded to buy on high hopes for combined flu/COVID vaccine and oncology pipeline
Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines tha...
Moderna Stock Takes Off on Cancer Vaccine News
Moderna stock shot up after Merck said it is exercising an option to work on a personalized cancer vaccine with the Covid-19 vaccine maker. Merck (ticker: MRK) will pay Moderna (MRNA) $250 million for...
Moderna Stock Surges. China Would Be a Big Market.
Text size Moderna stock has gotten a boost from the CEO’s comments about China. Photo by Justin Sullivan/Getty Images Moderna ’s Covid-19 vaccine has been wildly successful, but its stock has be...
Novavax slashes sales guidance in half, stock plunges 34%
Novavax Inc. executives slashed their annual sales guidance in half Monday while wildly missing financial expectations, sending shares down more than 30% in after-hours trading. Novavax NVAX, -5.01% n...
Moderna CEO: No ‘Crazy’ Deals. We’re Giving Cash to Shareholders.
Text size Moderna CEO Stephane Bancel says his company will keep returning cash to investors until it finds a better way of creating value. Jason Alden/Bloomberg Moderna ’s CEO is feeling no pressure ...
Moderna’s Earnings Are Wednesday. Here’s What to Expect.
Text size Moderna is developing two vaccines for the fall, one for the U.S. and the other for international markets. Sean Gallup/Getty Images As the U.S. prepares for a broad Covid-19 booster campaign...
GSK Spins Off $36 Billion Consumer-Healthcare Business Haleon
GSK PLC completed the spinoff of its consumer-healthcare business, a bet that greater focus on innovative drugs and vaccines will help accelerate growth at the pharmaceuticals giant. The new stand-alo...
Pfizer Raises Covid-19 Vaccine Price 27%. What It Means for the Stock.
Text size Pfizer said it has signed a deal to supply the U.S. with vaccines in the fall, while Moderna has yet to announce a sale. Jacob King – WPA Pool / Getty Images Pfizer has raised the U.S....
Novavax’s New Covid-19 Vaccine Might Be Late to the Party
It’s one thing to arrive fashionably late to a party, it’s another thing to waltz in when the last guests are stumbling out the door. For Novavax , which on Tuesday cleared a key step toward U.S. Food...
Novavax posts first quarterly profit, but misses expectations
Shares of Novavax Inc. dropped more than 6% in the extended session Monday after the biotech company reported its first profitable quarter, but not by as much as Wall Street expected, and its sales we...
BioNTech Earnings Top Forecasts on Strong Sales of Covid-19 Vaccine
Text size BioNTech is continuing to work with Pfizer on follow-on Covid-19 vaccines. (Photo by THOMAS LOHNES/AFP via Getty Images) BioNTech , the German biotech company, reported first-quarter earning...
As Demand for Mental-Health Care Booms, Investors See Opportunities
Psychiatrists and psychologists once ran their own practices. Now the local therapist office could be controlled by a buyout king. Venture capitalists and private-equity firms are pouring billions of ...
Pfizer’s New CFO David Denton Negotiated One of the Biggest Healthcare Deals in History
Pfizer on Monday named a new chief financial officer with a resume that hints at the company’s plans to spend big with its Covid-19 vaccine windfall. David Denton is taking up the CFO role at Pfizer (...
Pfizer, Moderna and J&J Face Shareholder Pressure to Broaden Covid-19 Vaccine Access
Socially conscious investors and global-health activists are turning to shareholders to press Covid-19 vaccine manufacturers Pfizer Inc., Moderna Inc. and Johnson & Johnson to make more of their s...
Novavax’s Revenue Falls Short. Management Expects a Surge.
Text size A doctor handles a vial holding a potential coronavirus vaccine at a Novavax lab in 2020. Andrew Caballero-Reynolds/AFP via Getty Images The Covid-19 vaccine maker Novavax expects sales of b...
Covid-19 Vaccine Makers Face a New Rival as GlaxoSmithKline and Sanofi Prepare to Enter the Ring
As new Covid-19 cases fall, the postpandemic vaccine market grows more interesting. On Wednesday, GlaxoSmithKline and Sanofi, two of the world’s largest vaccine makers, said they would submit a Covid ...
What investors need to know about Pfizer’s latest downgrade
Pfizer’s PFE, -0.92% early-stage pipeline, though promising, is still too premature to make up for the looming loss of billions of dollars from the company’s COVID-19 franchise, which includes the vac...